-
Thursday, 01/20/2022
Researchers from the Hospital Clínic-IDIBAPS lead the CIBERSUCICOVID project, which is about to identify the risk factors and prognosis of the patients infected by COVID-19 ingressats to the ICUs since the pandemic is going to start in Spain
Researchers from the Hospital Clínic-IDIBAPS lead the CIBERSUCICOVID project, which is about to identify the risk factors and prognosis of the patients infected by COVID-19 ingressats to the ICUs since the pandemic is going to start in Spain
Dr. Antoni Torres is the coordinator of the CIBERESUCICOVID project: Risk factors and prognosis of patients infected by COVID-19 and follow-up to any of the patients who have entered the Spanish ICUs.
The project is developed by researchers of the CIBER of Respiratory Diseases (CIBERES) and coordinated from the Hospital Clínic-IDIBAPS lead by Dr Antoni Torres.
The project forms part of the investigations carried out through the COVID-19 Fund at the end of the year 2020 and managed by the ISCIII, and will receive a total financing of 1,750,000 euros. He has comptat, així mateix, with the support of the Spanish Society of Intensive Critical Medicine and Coronary Unit (SEMICYUC) and the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR), with the participation of the Barcelona Supercomputing Center (BSC).
The main results show that the mortality rate of the patients entered by COVID-19 to the Spanish ICUs will be 31%.
CIBERESUCICOVID started in February 2020 and ends on December 31, 2021, has had the participation of more than 5,700 patients, enrolled in 69 Spanish ICUs, and has analyzed 1,068 samples of blood for the studies of epigenetics and biomarkers. Among the conclusions, it is worth highlighting the death rate at any of the high hospital, since, according to the results, more than 1% of the patients who have been in intensive cures. In addition, the CIBERES researchers have also identified the acquisition of an intra-hospital (nosocomial) pneumonia during entry with a factor associated with the persistence of coronavirus symptoms after three months. “We have studied the effect of corticosteroids on in-hospital mortality, finding several phenotypes in which no benefit is observed depending on age, initial severity, inflammatory status, and the absence of lymphopenia. Our results, therefore, will help to define which serious patients should receive corticosteroids ”, explains Torres
-
Monday, 10/11/2021
A new article of SARS-CoV-2 is published in Journal of Internal Medicine.
A new article is published in Journal of Internal Medicine.
The article is entitled: Low anti‐SARS‐CoV‐2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID‐19 patients.
In this article we studied the impact of antiSARS-CoV-2 S antibodies levels on survival, viral RNA-load in plasma, and N-antigenaemia in 92 COVID-19 patients over ICU admission. The corresponding author is Dr Antoni Torres.
-
Tuesday, 09/28/2021
Original Research Article has been published recently on the Critical Care Journal
Original Research Article has been published recently on the Critical Care Journal
The article is entitled: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients.
In this study comparing changes in parameters between day 1 and day 3 of mechanical ventilation in COVID-19 ARDS patients, a higher ventilatory ratio at day 1 and more importantly an increase in the ratio by day 3 were significant predictors of in-hospital mortality. The significance of this finding is not completely understood but might reflect vascular microthrombosis phenomena and/or alveolar edema, factors associated with increased physiologic dead space. The first co-authors are Antoni Torres and Anna Motos.
-
Tuesday, 09/28/2021
Original Research Article has been published recently on the European Respiratory Research Journal.
Original Research Article has been published recently on the European Respiratory Research Journal.
The article is entitled: Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study.This article talks about that follow-up cultures on day 3 after a VAP diagnosis can help the clinician stratify patients. Those patients who present early with superinfection have
worse ICU mortality, worse 90-day mortality and require more days of mechanical
ventilation. The first author is Dr Adrian Ceccato -
Thursday, 09/23/2021
Physiotherapist Nona Rovira joins IAMR group on September 1st 2021
Physiotherapist Nona Rovira joins IAMR group on September 1st 2021
She will focus on the pulmonary rehabilitation in patients with Bronchiectasis non associated to Cystic Fibrosis.
Nona Rovira has joint the research group in order to work on the pulmonary rehabilitation in patients with Bronchiectasis non associated to Cystic Fibrosis (BQ-noFQ).
-
Thursday, 09/16/2021
SEPAR Awards to our researchers
-
Wednesday, 07/14/2021
Thank you to all Data Entry and Monitoring teams who have participated in the Great Research Project: CIBERESUCICOVID
-
Tuesday, 07/06/2021
The 31st European Congress of Clinical Microbiology and Infectious Diseases
Our research group in the Congress
The 31st European Congress of Clinical Microbiology and Infectious Diseases, ECCMID, will be held in July 9-12. Our researchers will participate in it with the following:
Anna Motos, MSc, will present for 10 minutes the Abstract number 3128 entitled: Incidence and characteristics of ventilator-associated pneumonia patients with COVID-19: a multi-center study. July 9th, 15.50h.
The poster of Ruben López. MSc, entilted: The most powerful hypervariable regions of 16S rRNA for taxa identififacion of sputum has been selected as a Highly Rated e-poster, he will be availbale for questions during 20 minutes. July July 9th, 9am.
Dr Alex Soriano will present an Oral Session the poster entilted: Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity matched analysis. July 10th, 17.15h. Dr Catia Cillóniz is one of the authors of this poster.
She has 2 e-poster available during the Congress entilted: “Sepsis in relation to lymphopenia in community-acquired pneumonia” and “The value of C-reactive protein-to-lymphocyte ratio in predicting the severity of SARS Coronavirus 2 (SARS-CoV-2) pneumònia”
Dr Laia Fernández-Barat has an e-poster entilted: “Identification of highly immunogenic epitopes in the SARS-COV-2 Spike protein to produce neutralizing monoclonal antibodies for treatment” available during the Congress.
-
Monday, 07/05/2021
Dr Victoria Alcaraz has received the ERS Young Scientist Sponsorship
-
Monday, 07/05/2021
Patrícia Oscanoa receives the ERS Young Scientist Sponsorhip by the ECCMID
